KVP Capital Advisors, LP
An institutional investment manager in SAN FRANCISCO, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 13, 2026. SEC CIK 1858198.
- Reported value$136.2m
- Positions35
Holdings: 35 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Praxis Precision Medicines IPRAX | COM NEW | 74006W207 | 14.4 | 10.5% | 42,900 | Unchanged | |
| Whitehawk Therapeutics IncWHWK | COM | 00032Q104 | 9.9 | 7.3% | 2,165,997 | Unchanged | |
| Erasca IncERAS | COM | 29479A108 | 8.3 | 6.1% | 455,000 | Added+115,000 | |
| Trevi Therapeutics IncTRVI | COM | 89532M101 | 7.7 | 5.7% | 414,000 | Unchanged | |
| Sutro Biopharma IncSTRO | COM SHS | 869367201 | 7.5 | 5.5% | 226,575 | Unchanged | |
| Tango Therapeutics IncTNGX | COM | 87583X109 | 7.2 | 5.3% | 230,264 | Unchanged | |
| MBX Biosciences IncMBX | COM | 55287L101 | 6.7 | 4.9% | 121,524 | Unchanged | |
| Protagonist Therapeutics IncPTGX | COM | 74366E102 | 6.5 | 4.8% | 53,000 | Unchanged | |
| Edgewise Therapeutics IncEWTX | COM | 28036F105 | 5.4 | 4.0% | 133,000 | Unchanged | |
| Tandem Diabetes Care IncTNDM | COM NEW | 875372203 | 4.5 | 3.3% | 301,000 | New+301,000 | |
| Disc Medicine IncIRON | COM | 254604101 | 4.3 | 3.1% | 58,250 | Unchanged | |
| Savara IncSVRA | COM | 805111101 | 3.7 | 2.7% | 605,280 | Unchanged | |
| Arrivent Biopharma IncAVBP | COM | 04272N102 | 3.5 | 2.6% | 102,000 | New+102,000 | |
| Insmed IncINSM | COM PAR $.01 | 457669307 | 3.0 | 2.2% | 28,497 | Unchanged | |
| Achieve Life Sciences IncACHV | COM | 004468500 | 3.0 | 2.2% | 462,355 | Unchanged | |
| Ideaya Biosciences IncIDYA | COM | 45166A102 | 3.0 | 2.2% | 79,700 | Unchanged | |
| Ocular Therapeutix IncOCUL | COM | 67576A100 | 2.9 | 2.2% | 300,000 | Unchanged | |
| Axsome Therapeutics Inc.AXSM | COM | 05464T104 | 2.9 | 2.2% | 12,000 | Reduced−24,200 | |
| Design Therapeutics IncDSGN | COM | 25056L103 | 2.7 | 2.0% | 185,000 | New+185,000 | |
| United Therapeutics Corp DelUTHR | COM | 91307C102 | 2.6 | 1.9% | 4,750 | Unchanged | |
| Scholar Rock HLDG CorpSRRK | COM | 80706P103 | 2.5 | 1.8% | 45,000 | Unchanged | |
| Immix Biopharma IncIMMX | COM | 45258H106 | 2.4 | 1.7% | 230,423 | Unchanged | |
| Viridian Therapeutics IncVRDN | COM | 92790C104 | 2.3 | 1.7% | 125,000 | Unchanged | |
| Mineralys Therapeutics IncMLYS | COM | 603170101 | 2.3 | 1.7% | 84,168 | New+84,168 | |
| Bright Minds Biosciences IncDRUG | COM NEW | 10919W405 | 2.2 | 1.6% | 31,813 | Unchanged | |
| Travere Therapeutics IncTVTX | COM | 89422G107 | 2.2 | 1.6% | 39,000 | Reduced−52,000 | |
| Zura Bio Ltd | CLASS A ORD SHS | G9TY5A101 | 2.2 | 1.6% | 373,128 | Unchanged | |
| Artiva Biotherapeutics IncARTV | COM | 04317A107 | 1.9 | 1.4% | 200,000 | New+200,000 | |
| Nektar TherapeuticsNKTR | COM NEW | 640268306 | 1.9 | 1.4% | 26,900 | Unchanged | |
| Compass Therapeutics IncCMPX | COM | 20454B104 | 1.7 | 1.2% | 771,000 | Added+271,000 | |
| Cabaletta Bio IncCABA | COM | 12674W109 | 1.6 | 1.2% | 505,431 | Unchanged | |
| Vera Therapeutics IncVERA | CL A | 92337R101 | 1.4 | 1.0% | 32,700 | Unchanged | |
| Evolus IncEOLS | COM | 30052C107 | 1.0 | 0.8% | 150,000 | New+150,000 | |
| Celcuity IncCELC | COM | 15102K100 | 0.4 | 0.3% | 4,000 | Unchanged | |
| Vyne Therapeutics Inc | COM | 92941V308 | 0.3 | 0.2% | 500,551 | Unchanged |
Sold out: 3 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Revolution Medicines IncRVMD | COM | 76155X100 | 0.0 | 0.0% | 0 | Sold out−40,200 | |
| Soleno Therapeutics Inc | COM | 834203309 | 0.0 | 0.0% | 0 | Sold out−59,700 | |
| Terns Pharmaceuticals Inc | COM | 880881107 | 0.0 | 0.0% | 0 | Sold out−440,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-095988 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.